Skip to content
Veracyte is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment.
The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, colon cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco, California.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Key Leadership Promotions to Advance Its Strategic Global Vision
Tina Nova , Ph.D., Appointed President of CLIA U.S. Business Stephane Debono Named General Manager of IVD and EMEA Organizations Giulia C. Kennedy , Ph.D., Named Global Chief Scientific Officer and Chief Medical Officer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 6, 2022-- Veracyte, Inc .
Toggle Summary Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 14, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today the publication of clinical utility data confirming the ability of the Envisia Genomic Classifier to improve diagnostic and treatment decision-making for patients with idiopathic pulmonary


There are currently no events to display.


Title Documents

Corporate Presentation December 2021